Forest Laboratories, Inc. (Public, NYSE:FRX) Forest Laboratories recruitment to resume in stroke trial Forest Laboratories Inc. (FRX) plans to resume patient enrollment in its DIAS-2 Phase IIb/III desmoteplase study after an independent data monitoring committee reviewed data concerning a potential safety signal.
http://tech.groups.yahoo.com/group/biotech-news/ http://www.arizonabiotech.com/ http://www.azhttp.com/ http://www.arizonabiotech.com/ http://groups.yahoo.com/group/biotech-news/ http://www.arizonaentrepreneurs.com/ http://www.azhttp.com/ Yahoo! Groups Links <*> To visit your group on the web, go to: http://groups.yahoo.com/group/biotech-news/ <*> Your email settings: Individual Email | Traditional <*> To change settings online go to: http://groups.yahoo.com/group/biotech-news/join (Yahoo! ID required) <*> To change settings via email: mailto:[EMAIL PROTECTED] mailto:[EMAIL PROTECTED] <*> To unsubscribe from this group, send an email to: [EMAIL PROTECTED] <*> Your use of Yahoo! Groups is subject to: http://docs.yahoo.com/info/terms/